DRREDDY vs WOCKPHARMA: Stock Comparison

Dr Reddys Laboratories Ltd vs Wockhardt Ltd

Live data: 22 July 2026, 3:02 PM IST • Source: NSE and company filings

Dr Reddys Laboratories Ltd is the larger company by market capitalisation. Dr Reddys Laboratories Ltd shows a lower P/E, a higher ROE and a higher dividend yield, while Wockhardt Ltd shows faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Dr Reddys Laboratories Ltd and Wockhardt Ltd on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, DRREDDY is more favourable on 8 of 13 scored metrics and WOCKPHARMA on 5These counts are context-free and are not an overall rating.

Key Differences

Market Cap
DRREDDY is the larger company
₹98,815 Cr vs ₹30,362 Cr
P/E Ratio
DRREDDY has a lower P/E
24x vs 144.46x
P/B Ratio
DRREDDY has a lower P/B
2.66x vs 6.23x
EPS
DRREDDY has higher earnings per share
₹51.37 vs ₹13.1
Dividend Yield
DRREDDY has a higher dividend yield
0.65% vs 0%
Revenue Growth (TTM YoY)
WOCKPHARMA has faster revenue growth
26% vs -11.6%
EPS Growth (TTM YoY)
WOCKPHARMA has faster EPS growth
0% vs -86.2%
Qtr Sales Growth
WOCKPHARMA has stronger quarterly sales growth
29.9% vs -11.5%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricDRREDDYWOCKPHARMA
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricDRREDDYWOCKPHARMA
Live Price₹1,183.7₹1,865.9
Day Change-1.85%-1.6%
Volume21.17 L7.19 L
52-Week High₹1,414.9₹2,422.3
52-Week Low₹1,148.4₹1,086.7
Distance from 52W High-16.34%-22.97%

Valuation

MetricDRREDDYWOCKPHARMA
Market Cap₹98,815 Cr₹30,362 Cr
P/E Ratio24x144.46x
P/B Ratio2.66x6.23x
EPS₹51.37₹13.1
Book Value₹452.82₹304
Dividend Yield0.65%0%

Growth

MetricDRREDDYWOCKPHARMA
Revenue Growth (TTM YoY)-11.6%26%
EPS Growth (TTM YoY)-86.2%0%
Qtr Sales Growth-11.5%29.9%
Qtr Profit Growth-86.1%688%

Profitability & Leverage

MetricDRREDDYWOCKPHARMA
ROE11.2%6.11%
ROCE13%7.55%
Net Margin12.76%3.3%
Operating Margin19.2%19.3%
Debt to Equity0.2x0.45x

Shareholding

As of Mar 2026 • change vs previous quarter
MetricDRREDDYWOCKPHARMA
Promoter Holding26.63% 0.01 pp49.08%
FII Holding33.08% 0.12 pp7.09% 0.1 pp
DII Holding30.72% 0.28 pp10.96% 0.41 pp
Public Holding9.33% 0.14 pp32.83% 0.52 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Dr Reddys Laboratories Ltd and Wockhardt Ltd.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.